Human T lymphocytes can be activated by interaction with different stimuli, including antigens, mitogenic lectins, and antibodies directed to a number of wellcharacterized cell surface membrane structures such as the CD3TCR complex, CD2 and CD28 (Tp44), and other less studied structures such as Tp45, Tp90, and Tp103 (CB.1) (1-7). Other activating agents such as the tumor promoter phorbol esters are also able to trigger the proliferation of resting T cells, but they require the presence of other comitogenic signals provided by Cat ' ionophores or antibodies specific for CD3, CD2, or CD28 (8) (9) (10) (11) (12) .
During activation, T cells acquire a number of cell surface glycoproteins that are expressed de novo after distinct kinetics of appearance . Some molecules such as IL-2, transferrin and insulin receptors, and 4F2 and EA-1 antigens appear early, even before DNA synthesis (13) (14) (15) (16) (17) (18) . Others such as HLA-DR, CB .1, Ta-1, TLiSAI, T10, and VLA-1 appear later, on activated cells (13, (19) (20) (21) (22) (23) (24) . In addition, new epitopes have been detected after activation on human CD2 and murine T200 molecules (3, 25) .
Antibodies specific for hormone or growth factor receptors have been shown to mimic the functional effects of their ligands (26) (27) (28) . Therefore, we have explored the possibility that T cells might receive inductive proliferation signals by mAbs directed to certain activation structures . This has been analyzed by preparing mAbs to activated T lymphocytes and selecting for mAbs that both recognize activation structures and induce T cell proliferation. In the course of these studies, five mAbs have been isolated against activation molecules that are rapidly expressed on resting lymphocytes upon treatment with different stimuli and that trigger T cell proliferation and IL-2 synthesis in the presence of PMA. All mAbs are directed to an identical disulphide-linked heterodimeric structure designated as activation inducer molecule (AIM).' In this paper we characterize the structure and function of this molecule .
The cultures were maintained in humidified atmosphere containing 5% C02 for 72 h. Cell proliferation was estimated by [ 3H]TdR (1 gCi = 37 KBq; New England Nuclear, Boston, MA) incorporation during the last 16 h of culture . Cells were harvested and the radioactivity was measured in a liquid scintillation counter.
IL-2 Production Assay. PBL (2 x 105 cells/well) were cultured in 96-well microtiter plates . The cells were activated with culture supernatants (50 ttl) from different mAbs or 1 % PHA in either the presence or absence of different concentrations of PMA . After 24 h, culture supernatants were assayed for IL-2 activity as described (42) using the mouse T cell line CTLL2. The IL-2 concentration of each sample was referred to a standard preparation (National Institutes of Health, Bethesda, MD) and expressed in units/milliter.
Analysis of IL-2-R Expression . PBL were incubated in plastic plates (24 wells ; Costar, Cambridge, MA) coated with purified anti-AIM TPI/8, anti-CD3 T3b, and antiVLA HP2/1 mAb in the presence and absence of PMA . Culture plates were pretreated overnight with the purified mAb diluted in PBS (20 Rg/ml, 250 pl/well) and throughly washed with medium before the addition of PBL (2 x 106 cells/ml) . Cultures were set up either in the absence or presence of PMA (2 ng/ml) . After 24 h, cell cultures were harvested and the expression of IL-2-11 (CD25) was analyzed by immunofluorescence flow cytometry.
Results
Characterization of AIM Antigens . mAbs were obtained against human PBL activated for 24 h with a comitogenic mixture of PMA and anti-CD3 mAbs. Antibodies were selected by their reactivity with activated PBL but not with resting cells, and by their ability to induce cell proliferation in the presence of PMA. Five different cloned mAb-secreting hybridoma lines (TP) were obtained that fulfilled both selection criteria . As shown in Table I , the anti-AIM TP mAb triggered a high proliferative response of PBL in the presence of PMA, comparable in magnitude to that induced by anti-CD3 mAb. However, the anti-AIM mAbs were not able to directly activate PBL in the absence of PMA as opposed to the anti-CD3 mAbs.
To characterize the target structures recognized by the anti-AIM mAb, immunoprecipitation analyses were carried out from 125 1-labeled cell lysates of either resting or activated PBL (Fig . 1) . The five selected TP mAbs precipitated an identical two- chain structure containing polypeptide subunits of 33 and 27 kD from activated PBL ( Fig. 1 A, lanes 8-12) , but no material was precipitated from resting PBL ( Fig.  1 B, lanes 8-12) . Similarly, the IL-2-R molecule was selectively precipitated from activated PBL (Fig. 1, A and B, lane 2) . Conversely, the labeled CD3 polypeptides were absent in precipitates with two different anti-CD3 mAbs from activated PBL ( Fig. 1 A, lanes 6 and 7) and were detected in the precipitates from resting PBL ( Fig. 1 B, lanes 6 and 7) . The CD3 antigen is modulated by this treatment and disappeared from the cell surface membrane as described in previous reports (43, 44) . Other antigens such as CD2, CD8, and HLA-DR ( Fig. 1 A and B , lanes 3-5, respectively) were also included for comparison. The AIM antigen complex appeared to be a distinct molecular entity from the IL-2-R (CD25 antigen, 60 kD), the CD2 (50 kD), CD8 (32 kD), or HLA-DR (34/29 kD) molecules ( Fig. 1 A, lanes 2-5, respectively). The AIM antigens displayed a molecular mass of 60 kD when analyzed under nonreducing conditions that correspond to the sum of the molecular weights of the two polypeptides resolved under reducing conditions (Fig. 2) . Immunoprecipitation of AIM antigens from activated and nonactivated PBL. Studies of expression of AIM antigens on resting and activated PBL were also performed by immunofluorescence flow cytometry. Resting PBL did not express the AIM antigens (Fig . 3 A) , whereas the majority of PBL activated for 24 h with PMA and anti-CD3 mAbs were clearly stained by anti-AIM mAbs (Fig. 3 C) . A high proportion (86%) of the resulting activated cells were CD2+ T lymphocytes (data not shown) . The expression of AIM under these activation conditions was higher than that of other activation molecules such as the IL-2-R, both in terms of number of positive cells and fluorescence intensity (Fig. 3 C-D) .
These results indicate that AIM antigens are disulphide-linked heterodimeric structures selectively expressed on activated PBL and biochemically unrelated to other activation antigens such as IL-2-R .
Induction ofAIMExpression. We analyzed the capacity ofdifferent inductive stimuli or some mitogenic combinations to induce AIM expression. These comparative studies indicated that phorbol ester (PMA) was the strongest inducer of AIM expression even in the absence of other comitogenic signals (Fig. 4) . Stimuli such as PHA and anti-CD3 mAbs were also able to trigger AIM expression . In contrast, the Cat + ionophore A23187 failed to induce AIM antigens by itself. Interestingly, the AIM expression observed on PBL activated for 24 h with different mitogens was significantly higher when compared with PBL activated for 3 d (Fig . 4) . Therefore, it was of interest to explore the sequence of appearance of AIM on PBL treated with PMA as compared with that of other early activation antigens . As observed in Fig. 5 , 75 % ofPBL expressed AIM antigen after 3 h oftreatment. The peak of AIM expression was reached at 24 h and then gradually decreased. The kinetics showed that AIM expression considerably preceded that ofIL-2-R, and even that ofthe 4F2 molecule. Nevertheless, AIM is an activation antigen that is de novo synthesized by PBL upon addition ofthe activating agent since the induction of its expression on PBL by PMA was inhibited by pretreatment of cells with either inhibitors ofprotein or RNA synthesis (data not shown) .
These results clearly showed that AIM is an activation antigen of lymphocytes that can be induced very rapidly by mitogenic stimuli such as phorbol esters, PHA, and anti-CD3 mAbs .
Induction of Cell Proliferation by Anti AIM mAb. The comitogenic effect triggered by anti-AIM mAb was analyzed in more detail by using different concentrations of purified anti-AIM TPl/8 mAbs and PMA (Fig. 6) . The anti-AIM was able to mediate its inductive effect on proliferation at 0.5 wg/ml and the effect was maintained within a wide range of mAb concentrations (0.5-50 wg/ml) . The purified anti-CD3 mAb, included for comparison, triggered proliferation at lower concentrations than anti-AIM mAb (Fig. 6 A) . The difference in the requirement ofanti-AIM mAb doses compared with anti-CD3 could be attributed to the intrinsic characteristics of the CD3TCR antigen complex through which cell proliferation can be triggered without the requirement of any other comitogenic signal by using minor amounts of antibody.
The functional effect on PBL proliferation mediated by anti-AIM mAb required concentrations of PMA equal or higher than 0.5 ng/ml (Fig. 6 B) . This submitogenic concentration of PMA is enough to induce AIM expression (not shown) and, subsequently, the binding of anti-AIM mAb triggers the proliferative response. Both the expression of AIM and the proliferative response induced by PMA and anti-AIM mAb were observed on purified T lymphocytes (Table II , and data not shown) . Moreover, the proliferative effects were also induced by anti-AIM mAb on purified CD4 T lymphocytes and, to a lower extent, on purified CD8 T cells (Table II) . Thus, it appears that the effects of anti-AIM mAbs are not dependent on the presence of accessory cells. 
As
shown above, other stimuli such as PHA or anti-CD3 were also able to induce AIM expression . Therefore, the comitogenic effect of anti-AIM mAb with different stimuli was investigated (Table III) .
The culture of PBL with anti-AIM mAb in the   TABLE   II   Effect of Anti-AIM mAb on the Proliferation of Purled T Lymphocytes and CD4 and CD8 T Cell Subsets Different purified peripheral blood T cell populations (2 x 105 cells/well) were cultured with 10 pg/ml of purified anti-AIM TP1/8 mAbs in either the presence or the absence of PMA (2 ng/ml) .
[3H]TdR incorporation was measured in triplicate on day 3 presence of either PHA or anti-CD3 resulted in an enhancement ofT cell proliferation as compared with the responses to PHA or anti-CD3 alone. As expected, no proliferation was obtained with the combination of anti-AIM mAb and the Cat+ ionophore A23187, an agent that, as shown above, does not induce AIM expression . All these results may indicate that anti-AIM mAb are providing the cells with complementary signal(s) to protein kinase C activation . On the other hand, it appears that binding of anti-AIM mAb to its target structure synergized with the proliferative signals triggered by anti-CD3 or PHA.
TheEffect ofAntiAIMnzAb on CellProliferation Is Exerted Via IL-2/IL-2-R Pathway. The effect of different anti-AIM mAbs on the IL-2 production by PBL in the presence ofdifferent doses of PMA was examined (Table IV ). An inductive effect on the IL-2 secretion by PBL was observed with three different anti-AIM mAbs in a PMA dosedependent fashion, whereas no IL-2 synthesis was seen in the absence of PMA. The magnitude of the IL-2 production caused by the anti-AIM mAbs at the highest PMA concentration was comparable to that induced by either anti-CD3 mAb or PMA under the same experimental conditions . Interestingly, a fourth anti-AIM mAb (TPl/55) was not able to induce detectable IL-2 secretion on PBL in spite of staining activated cells with the highest fluorescence intensity (Fig. 3) . This is in agreement with proliferation results shown above where the anti-AIM TPl/55 mAb was the one displaying the lowest comitogenic effect (Tables I and III) .
Next, it was of interest to study whether PBL activated through AIM were able to express IL-2-R molecules. PBL activated with PMA in the presence of anti-AIM expressed IL-2-R molecules similarly to cells activated with anti-CD3 (Fig. 8) . Conversely, PBL cultured with purified anti VLA control mAbs did not express detectable IL-2-R molecules.
Further evidence that the PBL proliferation triggered by anti-AIM mAbs was directed via the IL2/IL-2-R pathway was obtained from inhibition experiments with two different anti-IL-2-R mAbs. As shown in Table V , both anti-IL-2-receptor mAbs were able to virtually abrogate the proliferation mediated by antiAIM mAbs and PMA.
Discussion
In the present study, the identification and initial biochemical and functional characterization of an AIM involved in the T cell activation mechanism is reported. A functional approach was undertaken in order to identify activation antigens through which T cells might receive mitogenic signals. Thus, the different mAbs that recognize the AIM molecule were initially selected by their ability to induce high proliferative responses in combination with phorbol esters .
The structure of the AIM molecule has been partially characterized. It is formed by a disulphide-linked 60-kD heterodimeric complex with polypeptide subunits of 33 and 27 kD. Interestingly, the AIM molecules are activation antigens expressed by activated T lymphocytes but absent on resting peripheral blood T cells. AIM antigens are clearly distinct molecular entities from most well-characterized human cell surface structures functionally involved in different molecular activation pathways. Induction of the expression of IL-2-R by anti-AIM mAbs . PBL were incubated into plates coated with purified anti-CD3, anti-AIM, or antiVLA control mAbs at 5 gg/well in either the absence or the presence of PMA (2 ng/ml). Cultures were harvested after 24 h. Cells were stained with either anti-CD25 or anti-CD45 mAbs and analyzed by flow cytometry. X63 was used as a negative control (dotted lines) . Induced by anti-AIM rnAbs PBL were activated with PMA (2 ng/ml) and two different concentrations of TP1/8 anti-AIM mAbs in the presence of culture supernatants of anti-IL2-R mAbs (250 ul/ml) or anti-CD45 mAbs (250 p1/ml) as a negative control . [ 3 H)TdR incorporation was measured in triplicate after 3 d .
Thus, on the basis of both cellular expression and molecular weight it is different from CD3, CD2, and CD28 (1) (2) (3) (4) and from the very recently described Tp45 and Tp90 (5, 6) . Unlike these molecules, which are present on resting T cells, the AIM molecule is an activation antigen selectively expressed by T lymphocytes activated by different stimuli.
After activation with phorbol esters, the AIM appearance can be detected earlier than other activation antigens such as IL-2-R and 4F2. In addition, AIM can also be distinguished from early activation structures such as IL-2-R (14), transferrin receptor (15) , and 4F2 (17) by both molecular weight and function . It is also clearly different from other intermediate and late activation antigens such as TLiSa 1 (22), VLA-1 (24, 45) , CB .1 (20) , Tal (21), T305 (46) , Tact (47) , and LDAI (48) . AIM and the recently described EA-1 (18) are similar in both molecular weight and kinetics of appearance . However, no functional role has been found for the EA-1 antigen, whereas the functional relevance of AIM molecules on the triggering of T cell activation and proliferation has been clearly demonstrated in this study. Furthermore, additional differences in cell distribution can also be appreciated. Thus, the EA-1 is expressed on the majority (60%) o£ immature thymocytes (18) , whereas the AIM antigen is only detected in a small subset (8-10%) of medullary mature thymocytes . (Cebrian, M., et al ., unpublished results) . Comparative cell distribution and biochemical studies will be required to ascertain whether the antigenic determinants defined by the anti-EA-1 mAb and those defined by the anti-AIM are located on identical or distinct molecular structures . We have also found that one (TPl/55) out of the five anti-AIM TP mAbs presented in this study displayed different functional and FAGS staining characteristics. Despite its higher reactivity with activated T lymphocytes, the TPl/55 mAb has weak or no effect on the induction of T cell proliferation and IL-2 production, respectively. Structure-function relation studies are in progress to understand the distinct functional behavior of the AIM mAbs . Recently, Cosulich et al . (49) have described an mAb directed to an activation antigen with molecular characteristics similar to AIM structures that inhibit different IL-1-dependent proliferative responses. In this sense, it will be also of interest to search for other anti-AIM mAbs displaying inhibitory characteristics.
It is important to note that AIM molecules are T lymphocyte activation antigens through which agonistic proliferative signals can be triggered by mAb binding as opposed to other mAbs specific for molecules such as IL-2-R and transferrin receptor (14, 50-52), TLiSal (22) , and LDAi (48) which have been reported to mediate inhibitory effects on T cell function . It is conceivable that anti-AIM mAbs may mimic the binding of a physiological ligand to its receptor and therefore trigger a similar sequence of signals that include a strong induction ofthe IL-2 synthesis/IL-2-R expression pathway. This is similar to what has been described for phorbol esters and growth factors in other cellular models (26) (27) (28) . Thus, in the insulin system, insulin is needed to act in concert with phorbol esters or permeable diacyglycerol for the induction of cell proliferation and growth response of Swiss 3T3 cell line (27) . Similarly, the activation and proliferation of B lymphocytes triggered by mAbs directed to the B cell activation marker CD23 in conjunction with PMA have also been reported (53) , and it is also remarkable that a soluble proteolytic fragment ofCD23 may also mimic the effects of B cell growth factor (54) .
The AIM molecules appear to play an important role for transducing signals that are synergistic with those provided by phorbol esters, which are known to activate protein kinase C. The anti-AIM mAbs also enhance the proliferative response mediated by PHA or anti-CD3 mAb. The expression of AIM is induced by phorbol esters alone, and is thus presumably dependent on protein kinase C activation . Studies with inactive analogues of PMA failed to induce AIM expression, whereas exogenous phospholipase C that directly generates diacylglycerol also triggered significant AIM cellular expression (Cebrian, M ., et al., manuscript in preparation) . It appears clear in this system that phorbol esters are sufficient to induce AIM expression and, in a second step, binding of anti-AIM mAb allows the triggering of the cell proliferative response. Whether the antibody alone is mitogenic or whether it requires the persistent activation of protein kinase C will be a matter of further research. Alternatively, it is also possible to speculate whether AIM structures may represent ion transporter molecules that can be stabilized in an active conformation by mAb binding, providing a maintained signal complementary to that of protein kinase C activation . In this context, a Na+ /Ca2' exchanger role has been assigned to the lymphocyte early activation antigen 4F2 since anti-4F2 mAb exerted inhibitory effects in this cation exchanger activity (55) . The intracellular signals triggered by anti-AIM mAbs still remain unknown and are currently under investigation. Experiments are now in progress to determine wheter phosphoinositide turnover, Cat' fluxes, or intracytoplasmic pH are affected by anti-AIM mAb binding.
Summary
In this report, we describe a novel activation antigen that appears very early after T cell activation and is absent in resting lymphocytes, through which agonistic proliferative signals can be triggered by mAb binding. It has been designated as activation inducer molecule (AIM) and is a disulphide-linked heterodimeric structure containing two polypeptide chains of M, 33,000 and 27,000 . The expression of AIM can be induced by different activation stimuli such as PMA, PHA, or anti-CD3 mAb, but not by the Cat + ionophore A23187, and it precedes the expression of other activation molecules such as 4F2 or the IL-2-R . Once AIM antigens are expressed on lymphocytes after stimulation with submitogenic doses of PMA, the binding of anti-AIM mAbs triggers a strong proliferative response . Furthermore, a comitogenic effect of the anti-AIM mAbs is exerted in the presence of either PHA or anti-CD3 mAb . The activation of lymphocytes through AIM antigens induces both IL-2 and IL-2-R receptor synthesis and is inhibited by anti-IL-2-R mAbs.
